Substitute Form PTO-1449  (Modified)  U.S. Department of Commerce Patent and Trademark Office				Attorney's Docket No. Application No. 17109-013001 / 923 10/658,355				
List of Patents and Publications for Applicant's				Applicant Rene Gantier et a	Applicant Rene Gantier et al.			
Information Disclosure Statement  NOV 0 9 2004 및  (37 CFR §1.98(b))			Filing Date September 8, 200	September 8, 2003  Group Art Unit  1645  Group Art Unit				
		(Ely	40)					
		T.APLE	U.S. Pater	nt Documents				
Examiner Injtial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate	
Men	AA	3,171,820	03/02/65	Volz et al.	521	61	02/17/64	
	ΑВ	5,223,409	06/29/93	Ladner et al.	435	69.7	03/01/91	
	AC	6,013,478	01/11/00	Wells et al.	435	69.1	06/24/98	
	AD	6,171,820	01/09/01	Short	435	69.1	02/04/99	
4	AE	2003/0224404	12/04/03	Vega et al.	435	6	02/24/03	

	Foreig	n Patent Do	cuments or F	Published Foreign	Patent A	Application	าร	
Examiner	Desig.	Document	Publication	Country or			Trans	lation
Initial	ID D	Number	Date	Patent Office	Class	Subclass	Yes	No
Am	AF	01/61344	08/23/01	PCT				
Um	AG	01/025438	04/12/01	PCT				
Du	AH	04/022747	03/18/04	PCT				
Van	ΑI	04/022593	03/18/04	PCT				
M	AJ	0 240 224	10/07/87	EP				

(	Other Documents (include Author, Title, Date, and Place of Publication)				
Examiner Initial	Desig. ID	Document			
Pin	AK	Kuhn "Structural basis for the positional specificity of lipoxygenases" Prostaglandins and other lipid mediators 62(3):255-270 (2000)			
M	AL	Lewerenz et al. "Shared receptor components but distinct complexes for alpha and beta interferons"  J. Mol. Biol. 282(3):585-599 (1998)			
m	AM	Manetti et al. "Design and realization of a tailor-made enzyme to modify the molecular recognition of 2-arylpropionic esters by Candida rugosa lipase" Biochem. Biophys. Acta 1543(1): 146-158 (2000)			

Examiner Signature 3	Date Considered
EXAMÍNER: Initial if citation considered, whether or not citation is in conformance and not considered. Include copy of this form with next co	

Substitute Form PTO-1449 (Modified)

JAN 0 4 2005

S. Department of Commerce
Patent and Trademark Office

Attorney's Docket No. 17109-013001 / 923

Application No. 10/658,355

List of Pater and Publications for Applicant's Information Belosure Statement

Applicant
Rene Gantier et al.

Filing Date September 8, 2003 Group Art Unit
1645

(37 CFR §1.98(b))

**U.S. Patent Documents** Desig. Examiner **Document Publication** Filing Date Initial Number **Date Patentee** Class **Subclass** If Appropriate ID 4797368 01/10/89 Carter et al. 435 320 03/15/85 AA 08/18/92 AB 5139941 Muzyczka et al. 435 172.3 10/25/91 11/05/96 Ladner et al. 69.7 AC 5571698 435 06/18/93 AD 5723323 03/03/98 Kauffman et al. 435 172.3 12/02/94 Shenk et al. 435 ΑE 5753500 05/19/98 320.1 04/03/95 AF 5763239 06/09/98 Short et al. 435 172.1 06/18/96 5770434 06/23/98 Huse 435 252.33 AG 05/15/95 104 AH 5779434 07/14/98 De Long 415 02/06/97 Weber et al. 514 634 5798390 08/25/98 05/22/95 ΑI 69.7 AJ 5837500 11/17/98 Ladner et al. 435 04/03/95 5862514 01/19/99 Huse et al. 702 22 12/06/96 AK 69.7 AL 5871974 02/16/99 Huse 435 12/02/94 6001574 Short et al. 6 03/04/98 AM 12/14/99 435 435 05/02/00 6 AN 6057103 Short 08/26/97 A<sub>0</sub> 6096548 08/01/00 Stemmer 435 440 02/03/97 AP 6117679 09/12/00 Stemmer 435 440 05/25/96 435 325 07/17/97 6127175 10/03/00 Vigne et al. AQ 6132970 10/17/00 Stemmer 435 6 06/19/98 AR AS 6156509 12/05/00 435 6 11/12/97 Schellenberger 6165793 12/26/00 435 440 05/08/98 AT Stemmer 01/16/01 Short et al. 6 AU 6174673 435 06/16/98 ΑV 01/30/01 6180406 435 440 06/17/98 Stemmer AW 6238884 05/29/01 Short et al. 435 69.1 03/09/99

1	Foreign Patent Documents or Published Foreign Patent Applications								
ı	Examiner	Desig.	Document	Publication	Country or			Trans	slation
ı	Initial	ID	Number	Date	Patent Office	Class	Subclass	Yes	No

Huse

Examiner Signature

AX

6258530

Date Considered

6

12/30/94

435

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

07/10/01

Substitute Form (Modified)	- · · · · · · · · · · · · · · · · · · ·			Attorney's Docket No.   Application No.   17109-013001 / 923   10/658,355				
		d Publications n Disclosure S	for Applicant's tatement	Applicant Rene Gantier et	al.			
				Filing Date	^^	Group Art Unit		
(37 CFR §1.98	(b))			September 8, 20	03	1645 6	<u> 31                                    </u>	
	Foreig	n Patent Dod	cuments or Po	ublished Foreign	Patent A	Application	ns	
Examiner	Desig.	Document	Publication	Country or			Trans	lation
Initial	ID	Number	Date	Patent Office	Class	Subclass	Yes	No
pen	AY	02/16606	02/28/02	PCT			х	
Pan	AZ	99/11764	11/15/01	PCT				

3/11/1999 Other Documents (include Author, Title, Date, and Place of Publication) Desig. Examiner Document Initial ID Altschul et al., "Basic Local Alignment Search Tool", J. Molec. Biol., 215:403-410 (1990) BA Ashktorab et al., "Identification of Nuclear Proteins That Specifically Interact with Adeno-Associated Virus Type 2 Inverted Terminal Repeat Hairpin DNA", Journal of Virology, 63:3034-BBATCC accession no. VR-1449, "Simian virus 15", (accessed on 09/05/2002) BC ATCC accession no. VR-645, "Adeno-associated virus 1 deposited as Adeno-associated (satellite) BD virus type 1", (accessed on 09/05/2002) ATCC accession no. VR-646, "Adeno-associated virus 4 deposited as Adeno-associated virus type BE 4", (accessed on 09/05/2002) ATCC accession no. VR-680, "Adeno-associated virus 2 deposited as Adeno-associated virus type BF 2", (accessed on 09/05/2002) ATCC accession no. VR-681, "Adeno-associated virus 3 deposited as Adeno-associated virus type BG 3", (accessed on 09/05/2002) Atkinson et al., "A high-throughput hybridization method for titer determination of viruses and gene therapy vectors", Nucleic Acids Research., 26:2821-2823 (1998) BH Batchu et al., "Disassociation of Conventional DNA Binding and Endonuclease Activities by an Adeno-Associated Virus Rep78 Mutant", Biochemical And Biophysical Research Communications, BI 210:717-725 (1995) Beaton et al., "Expression from the Adeno-Associated Virus p5 and p19 Promoters Is Negatively BJ Regulated in trans by the rep Protein", Journal of Virology, 63:4450-4454 (1989) Beck-Sickinger et al., "Complete L-alanine scan of neuropeptide Y reveals ligands binding to Y1 BK and Y2 receptors with distinguished conformations", Eur. J. Biochem., 223:947-958 (1994) Carrillo et al., "The Multiple Sequence Alignment Problem in Biology", SIAM J. Applied Math, BL 48:1073-1082 (1988) Cassinotti et al., "Organization of the Adeno-Associated Virus (AAV) Capsid Gene: Mapping of a BM Minor Spliced mRNA Coding for Virus Capsid Protein 1", Virology, 167:176-184 (1988) Certified English Translation of PCT Patent Application No. WO 01/86291, "Method for BN Determining the Titer of Biological Agents in Living Target Cells." Certified English Translation of PCT Patent Application No. WO 02/16606, "Method for Massive BO Directed Mutagenesis." Chadeuf et al., "Efficient recombinant adeno-associated virus production by a stable rep-cap HeLa cell line correlates with adenovirus-induced amplification of the integrated rep-cap genome", J. Gene Med., 2:260-268 (2000)

Examiner Signature 3	Date Considered  Y 30 0 6					
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant.						

Substit (Modifi		n PTO-1449	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 17109-013001 / 923	Application No. 10/658,355		
Lis			d Publications for Applicant's n Disclosure Statement	Applicant Rene Gantier et al.			
				Filing Date	Group Art Unit		
(37 CF	R §1.98	(b))		September 8, 2003	1645 1631		
		Other D	ocuments (include Author, 1	litle, Date, and Place o	f Publication)		
Exam Init		Desig. ID		Document			
De	4	BQ	Charbord et al. "Normal human granu colony stimulating activity" Nouv. Re	ev. Fr. Hematol. 22: 357-370, (1	980)		
	,	BR	Chejanovsky et al., "Mutagenesis of a Effects on Viral DNA Replication", J.	Virology, 173:120-128 (1989)	•		
			Chejanovsky et al., "Mutation of a Co				
		BS	Associated Virus rep Gene Generates Virology, 64:1764-1770 (1990)		•		
		вт	Cullen et al., "Analysis of the Physica Intraepithelial and Invasive Cervical N	Neoplasm", Journal of Virology,	65:606-612 (1991)		
		BU	Davis et al. "High throughput method Therapy 5(8):1148-1152 (1998)				
		BV	Protein In Vitro", Journal of Virology,	of Charge Cluster Mutations in Adeno-Associated Virus Rep68 7, 73:2084-2093 (1999)			
		вw	Davis et al., "Mutational Analysis of A Activity on Partially Single-Stranded	Substrates", Journal of Virology	ogy, 74:2936-2942 (2000)		
		вх	Deng et al., "Site-Directed Mutagenes Analytical Biochemistry, 200:81-88 (	1992)			
		ВУ	Derwent # 013914049, WPI Acc. No. Patent Application WO 2001/44809 "I target cells, for selecting gene therapy theoretical curve"	Evaluating the performance of c	omplex biological agents in		
		BZ	Derwent # 014262217, WPI Acc. No. 2001/86291 A1, "Determining titer of vaccines, is based on measuring reactiperiod"	biological agent, useful e.g. for on with cells at constant concen	gene therapy vectors or tration, over a specified time		
		CA	Devereux et al., "A comprehensive set Research, 12(I):387-395 (1984)				
		СВ	Gavin et al., "Charge-to-Alanine Muta Proteins Yields Temperature-Sensitive 73:9433-9445 (1999)	e and Magnesium-Dependent Va	riants", Journal of Virology,		
		CC	Genbank accession no. NC_001401, N (accessed on 09/05/02)				
		CD	Genbank accession no. NC_001729, N (accessed on 09/05/02)				
		CE	Genbank accession no. NC_001829, N (accessed on 09/05/2002)				
		CF	Genbank accession no. NC_001863, N (accessed on 09/05/2002)	Nucleotide, "Adeno-associated v	irus 3B, complete genome",		
		CG	Genbank accession no. NC_002077, N (accessed on 09/05/2002)	Nucleotide, "Adeno-associated v	irus 1, complete genome",		
		СН	Gibbs et al., "Rational Scanning Mutagenesis of a Protein Kinase Identifies Functional Regions Involved in Catalysis and Substrate Interactions", Journal of Biology Chemistry, 266:8923-8931 (1991)				

Examiner Signature	Date Considered /
Vneli 5:	4/30/06
EXAMINER: Initial if citation considered, whether or not citation is in co	
conformance and not considered. Include copy of this form with next co	mmunication to applicant.

Substitute (Modified)	Form PTO-144	9 U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 17109-013001 / 923	Application No. 10/658,355
List of		nd Publications for Applicant's on Disclosure Statement	Applicant Rene Gantier et al.	
(37 CFR §	98(b))		Filing Date September 8, 2003	Group Art Unit 1645   63
(0. 0	Other D	ocuments (include Author,	Title, Date, and Place o	f Publication)
Examine			<u> </u>	
Initial	ID		Document	
Zu	CI	Gribskov et al., "Sigma factors from I proteins", Nucleic Acids Research, 14	l:6745-6763 (1986)	
	Cl	Hermonat et al., "Genetics of Adeno-Adeno-Associated Virus Type 2 Muta	ants", Journal of Virology, 51:32	9-339 (1984)
	СК	Hermonat, P.L., "Down-regulation of adeno-associated virus Rep78", Cance	er Letters, 81:129-136 (1994)	
	CL	Hill A.V., "The possible effects of the dissociation curves", Proceedings of t	e aggregation of the molecules of the Physiological, Journal of Phy	f haemogloblin on its siology, 40:iv-vii (1910)
	СМ	Hill et al., "XLVII. The Combination Monoxide", I. Biochem. J., 7:471-480		And With Carbon
	CN	Horer et al., "Mutational Analysis of A Heterologous and Homologous Prome	oters", Journal of Virology, 69:5	485-5496 (1995)
	со	Im et al., "Partial Purification of Ader		
plred		Biochemical Characterization", Journ	al of Virology, 66:1119-1128 (1	992)
RI	СР	Im et al., "The AAV Origin Binding I Endonuclease with DNA Helicase Ac	tivity", Cell, 61:447-457 (1990)	
	CQ	Kechli et al., "Expression of the Hum Inhibits HIV-1 Replication", Human	Gene Therapy, 9:587-590 (1998)	)
	CR	Kyostio et al., "Analysis of Adeno-As Their Abilities To Negatively Regulat 68:2947-2957 (1994)	te AAV p5 and p19 mRNA Leve	els", Journal of Virology,
	CS	Kyostio et al., "Identification of Muta Dominant-Negative For DNA Helicas Communications, 220:294-299 (1996	se Activity", Biochemical and B	iophysical Research
	СТ	Kyostio et al., "Negative Regulation of both the P5 Rep Binding Site and the Journal of Virology, 69:6787-6796 (1	Consensus ATP-Binding Motif 995)	of the AAV Rep68 Protein",
	CU	Marcello et al., "Adeno-Associated V 16 E2 Recruitment of the Transcriptio (2000)	onal Coactivator p300", Journal	of Virology, 74:9090-9098
	CV	Matsushita et al., "Localization of vor and Botrocetin by Charged-to-Alanin 275:11044-11049 (2000)	e Scanning Mutagenesis", Journ	al of Biology Chemistry,
	CW	McCarty et al., "Analysis of Mutation Vitro", Journal of Virology, 66:4050-	4057 (1992)	
	СХ	Mendelson et al., "Identification of the Antibodies to a Synthetic Oligopeptid	e trans-Acting Rep Proteins of A le", Journal of Virology, 60:823-	832 (1986)
	CY	Mittereder et al., "Evaluation of the C Therapy", Journal of Virology, 70:74		Adenovirus Vectors for Gene
	CZ	Moullier et al., "Comparative binding lymphocytes" European J. Biochem.	of wheat germ agglutinin and it	s succinylated form on
	DA	Needleman et al., "A General Method Sequence of Two Proteins", Journal o	Applicable to the Search for Si	

Examiner Signature	Date Considered ,
	L1/3n/25
102	7/20/06
EXAMINER: Initial if citation considered, whether or not citation is in a	onformance with MPEP 609; Draw line through citation if not in
conformance and not considered. Include copy of this form with next co	ommunication to applicant.

Substitute Fon (Modified)	m PTO-1449	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 17109-013001 / 923	Application No. 10/658,355	
		d Publications for Applicant's n Disclosure Statement	Applicant Rene Gantier et al.		
			Filing Date	Group Art Unit	
(37 CFR §1.98	3(b))		September 8, 2003	1645 (63)	
		ocuments (include Author,	Title, Date, and Place o	f Publication)	
Examiner	Desig.				
Initial	ID D		Document		
-011	DB	Nelson et al., "Characterization of Div			
		Whole-Virion Dot-Blot Method", Hu	m. Gene Ther., 9:2401-2405 (19	98)	
	DC	Ni et al., "In Vitro Replication of Ade 1138 (1994)			
	DD	Owens et al., "Adeno-Associated Vin			
	DD	Systems: Wild-Type and Dominant-N		the Viral Replication Origin",	
		Journal of Virology, 184:14-22 (1991) Owens et al., "Identification of a DNA	A-Binding Domain in the Amino	Terminus of Adeno-	
	DE	Associated Virus Rep Proteins," J. Vi		Tommus of Adono-	
		Owens et al., "In Vitro Resolution of .		Iairpin Termini by Wild-Type	
	DF	Rep Protein Is Inhibited by a Domina	nt-Negative Mutant of Rep", Jou	irnal of Virology, 66:1236-	
		1240 (1992)			
	DG	Pearson et al., "Improved tools for bio 85:2444-2448 (1988)			
		Press Release 10; "Nautilus Biotech a		SE: MBX) sign a distribution	
į	DH	agreement for rAAV high-producer co			
		http://www.nautilusbiotech.com/news	s-pressrelease 10.php3, accessed on (2/28/02)		
	DI	applications in directed evolution and	granted patent covering molecular fitness analysis with key d functional genomics target identification"; Paris- February 6, m/news-pressrelease11.php3, accessed on (2/28/02)		
	<u>.                                    </u>	Press Release 6; "Nautilus Biotech S			
	DJ	September 14, 2001; http://www.naut			
		(2/28/02)			
	DK	Press Release 7; "Nautilus Biotech op Paris- September 21, 2001; http://ww (2/28/02)			
	DL	Ropp et al., "Aequorea Green Fluores 21:309-317 (1995)	cent Protein Analysis by Flow C	Cytometry", Cytometry,	
	DM	Ruffing et al., "Mutations in the carbo viral infectivity: lack of an RGD integ			
	F33.7	Ryan et al., "Sequence Requirements	for Binding of Rep68 to the Ade	eno-Associated Virus Terminal	
	DN	Repeats", Journal of Virology, 70:154	12-1553 (1996)		
	DO	Salvetti et al., "Factors Influencing Ro Ther., 20:695-706 (1998)			
	DP	Samulski et al., "A Recombinant Plas Genome Can Be Excised In Vitro and 61:3096-3101 (1987)			
DQ Schumann et al. "Intracellular Ca2+ inhibits sm protein phosphatase type 2B and by direct intera 503-513, (1997)					
Ar.	DR.	Schwartz et al., "Matrices for Detection			
the onat.	Je Jr	Structure, National Biomedical Resea			
Res	DS	Smith et al., "Comparison of Biosequ	ences", Advances in Applied Ma	athematics, 2:482-489 (1981)	
Examiner Sign	eture	Do Q.	Date Considered		
110	al		4/30/06	Ab	
conformance	nicial if citations	on considered whether or not citation is in considered. Include copy of this form with next co	oniormance with MPEP 609; Draw III ommunication to applicant.	ie unough ciauon if not in	

Substitute For (Modified)	m PTO-1449	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 17109-013001 / 923	Application No. 10/658,355			
		d Publications for Applicant's n Disclosure Statement	Applicant Rene Gantier et al.				
(37 CFR §1.98	3(b))		Filing Date September 8, 2003	Group Art Unit			
(	Other D	ocuments (include Author,	Fitle, Date, and Place o	f Publication)			
Examiner Initial	Desig. ID		Document				
M	DT	Srivastava et al., "Nucleotide Sequence and Organization of the Adeno-Associated Virus 2 Genome", Journal of Virology, 45:555-564 (1983)					
	DU	Tessier et al., "Characterization of Adenovirus-Induced Inverted Terminal Repeat-Independent Amplification of Integrated Adeno-Associated Virus rep-cap Sequences", Journal of Virology, 75:375-383 (2001)					
	DV	Translation of PCT Patent Application WO 01/44809, "Methods for Screening or Assessing the Performance of a Collection of Biological Agents in Living Parget Cells, And Their Applications"					
	DW	Urabe et al., "Charged-to-Alanine Scanning Mutagenesis of the N-Terminal Half of Adeno- Associated Virus Type 2 Rep78 Protein", Journal of Virology, 23:2682-2693 (1999)					
	DX	Walker et al., "Mutational Analysis of Motifs", Journal of Virology, 71:6996	5-7004 (1997)				
	DY	Walker et al., "Mutational Analysis of the Adeno-Associated Virus Rep68 Protein: Identification of Critical Residues Necessary for Site-Specific Endonuclease Activity", Journal of Virology, 71:2722-2730 (1997)					
	DZ	Watson et al., "Molecular Biology of (1987)					
	EA	Weitzman et al., "Interaction of Wild-Type and Mutant Adeno-Associated Virus (AAV) Rep Proteins on AAV Hairpin DNA", Journal of Virology, 70:2240-2248 (1996)					
	EB	Weitzman et al., "Recruitment of Wild-Type and Recombinant Adeno-Associated Virus into Adenovirus Replication Centers", Journal of Virology, 70:1845-1854 (1996)					
	EC	Wu et al., "Mutational Analysis of the Adeno-Associated Virus Type 2 (AAV2) Capsid Gene and Construction of AAV2 Vectors with Altered Tropism", J. Virol., 74:8635-8647 (2000)					
	ED	Yang et al., "Analysis of the Termina Replication Proteins", Journal of Viro	logy, 67: 4442-4447 (1993)				
	EE	Yang et al., "Mutational Analysis of t 66:6058-6069 (1992)	he Adeno-Associated Virus rep				
1/	EF	Yoon et al., "Amino-Terminal Domai					

Examiner Signature

Date Considered

JB 0 0 6

EXAMINER: Initial if citation considered whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Chast	1	- C	
Sheet	ı.	of	1

Substitute Form PTO-1449 U.S. Department of Commerce						<b>)</b> .	
(Modified)	(Modified) Patent and Trademark Office		9   17109-013001 / 9	923	10/658,35	5	
		OIPE					
List of P	atents an	d Publications	for Applicant's	Applicant			
List of Patents and Publications for Applicant's Information Disclosure Statement				Rene Gantier et al.			
( 1000 m)			Filing Date		Group Art Unit		
				September 8, 200	)3	1645 (	21
(37 CFR §1.98	3(0))					1015 1 6	<u> </u>
		TO TO THE MARKET	U.S. Paten	t Documents			
Examiner	Desig.	Document	Publication				Filing Date
Initial	ID D	Number	Date	Patentee	Class	Subclass	If Appropriate
		none					

	Foreign Patent Documents or Published Foreign Patent Applications									
Examiner	Desig.	Document	Publication	Country or			Trans	lation		
Initial	ID	Number	Date	Patent Office	Class	Subclass	Yes	No		
Den	AA	01/25253	04/12/01	PCT						
	AB	01/32844	05/10/01	PCT						
	AC	95/23813	09/08/95	PCT						
·	AD	98/13487	04/02/98	PCT						
	AE	99/07833	02/18/99	PCT						
V	AF	99/11764	03/11/99	PCT						

	Other Documents (include Author, Title, Date, and Place of Publication)						
Examiner Initial	Desig.	Document					
maa	1.5	none					

Examiner Signature	Date Considered /
	1 1/1/06
- Marie 8	4126100
EXAMINER: Initial if citation considered, whether or not citation is in c	
conformance and not considered. Include copy of this form with next c	ommunication to applicant.

(37 CFR §1.98(b))

C1 4	1	- 5	4
Sheet	ı	of	- 1

1631

U.S. Department of Commerce Patent and Trademark Office Application No. rm PTO-1449 Attorney's Docket No. 17109-013001 / 923 10/658,355 Applicant List of Patents and Publications for Applicant's **Information Disclosure Statement** Rene Gantier et al. Filing Date Group Art Unit

September 8, 2003

U.S. Patent Documents								
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate	
Lu	AA	5017371	05/21/91	Cummins	424	85.6	01/06/88	
j	AB	5215741	06/01/93	Young et al.	424	85.7	10/30/90	
	AC	6036949	03/14/00	Richards et al.	424	85.7	03/05/98	
1/	AD	6506377	01/14/03	Cummins et al.	424	85.7	09/27/01	

Foreign Patent Documents or Published Foreign Patent Applications								
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Trans Yes	slation No
		none						

Other Documents (include Author, Title, Date, and Place of Publication)						
Examiner Initial	Desig. ID	Document				
		none				

	of .
EVAMINED: Initial if sitation topoldered whether or not citation is in conformance with MDED 60	<u> </u>

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in

conformance and not considered. Include copy of this form with next communication to applicant.

	- /c	SIPE 40				Sh	eet <u>1</u> of <u>1</u>	
Substitute Form PTO 1449  (Modified)  JAN. 0 4 2000 Patent and Trademark Office				Attorney's Docket No. 17109-013001 / 9	923	Application No 10/658,35		
List of Patents and Publications for Applicant's Information Dischesure Statement				Applicant Rene Gantier et al.				
(37 CFR §1.98(b))				Filing Date September 8, 200	Filing Date Group Art Unit September 8, 2003 1631			
1			U.S. Pater	nt Documents				
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate	
Am	AA	20020081574	6/27/2002	Collett et al.				
Den	AB	5925565	7/20/1999	Berlioz et al.				

	Foreign Patent Documents or Published Foreign Patent Applications											
Examiner	Desig.	Document	Publication	Country or			Trans	slation				
Initial	1D	Number	Date	Patent Office	Class	Subclass	Yes	No				
		none		•								

	Other Documents (include Author, Title, Date, and Place of Publication)								
Examiner	Desig.								
Initial	ID.	Document							
	<u> </u>	none							

Examiner Signature

Date Considered

UNCOP

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

3-17-04

·•						
FORM PTO-1449	ATTY. DOCKET NO.	SERIAL NO.	CONFIRM NO.			
	37851-923	10/658,355	3519			
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE	APPLICANT GANTIER et al.	CUSTOMER NO. 24961				
STATEMENT	FILING DATE	GROUP	·			
	September 8, 2003	-1644 (63	/			

<sup>\*</sup> If an asterisk is placed beside the reference number, a copy is NOT provided because the reference was previously cited by or submitted to the PTO in a prior application that is identified in the statement and relied upon for an earlier filing date under 35 U.S.C. 120. 37 C.F.R. § 1.98(d).

X+ Derwent English language abstract and/or English translation provided.

## U.S. PATENT DOCUMENTS

						0.0							
EXAMINER INITIAL	*Ref. Code		DI	OCUM	ENT N	IUMBI	R		DATE	NAME	CLASS	SUB CLASS	FILING DATE
	A	0	1	2	9	2	0	3	07/10/03	Vega et al.	424	233.1	12/17/01
<b>—</b>	В	0		2	9	5	8	4	07/10/03	Vega	435	5	12/13/00
		-0-	7	3	4	3	5	-,-	07/17/03	Vega et al.	435	69.1	12/17/01 >
	D-	0		7	-5	0	9	4	09/18/03	Vega	435	-5-	05/04/01
	E	٥	2	-2	4	4	-	4	12/04/03	Vega et al.	495	6	02/24/03
Un	F	4	ó	4	4	1	2	6	08/23/77	Cook et al.	424	243	07/09/76
De	G	4	3	6	4	9	2	3	12/21/82	Cook et al.	424	46	04/30/81
m	<del> </del>	4	4	1	4	2	0	9	11/08/83	Cook et al.	424	243	06/13/77
en		4	5	2	2	8	1	1	06/11/85	Eppstein et al.	514	2	07/08/82

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	*Ref. Code		DC	CUMI	ENT N	UMBE	R		DATE	COUNTRY	CLASS	SUB CLASS	Trans Yes	lation No
m	J	0	1	3	2	7	1	1	A2 05/10/01	PCT		<u> </u>		
1	К	0	1	4	4	8	0	9	A2 06/21/01	РСТ			ļ	X+
	L	0	1	8	6	2	9	1	A1 11/15/01	PCT				X+
	М	03	0	2	3.	0	3	2	A2 03/20/03	PCT				
	N	03	0	1	8	8	2	0	A2 03/06/03	PCT			<u> </u>	
	(0)	1	0	2	2	.3	3	5	07/26/00	EP		<u> </u>		

EXAMINER 2

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: RATIONAL DIRECTED PROTEIN EVOLUTION USING TWO-DIMENSIONAL RATIONAL MUTAGENESIS

**SCANNING** 

<sup>\*\*</sup> If an asterisk is placed beside the reference number, a copy is NOT provided because pursuant to the USPTO's waiver from the 37 CFR 1.98(a)(2)(i) requirement for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. national patent applications filed after June 30, 2003 and for all international applications that have entered the national stage under 35 USC 371 after June 30, 2003. See 37 CFR 1.491(b).

## ATTY, DOCKET NO. SERIAL NO. CONFIRM NO. **FORM PTO-1449** 10/658,355 3519 37851-923 **APPLICANT** CUSTOMER NO. LIST OF PATENTS AND PUBLICATIONS FOR GANTIER et al. 24961 APPLICANT'S INFORMATION DISCLOSURE STATEMENT FILING DATE **GROUP** September 8, 2003 <del>1644</del>-

X+ Derwent English language abstract and/or English translation provided.

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	*Ref. Code		DOCUMENT NUMBER				DATE	COUNTRY	CLASS	SUB CLASS	Trans Yes	lation No		
	P	-2	8	0	2	-6_	4	_5_	A1 06/22/01	-FR				~X±
	-0	2_	8_	-0-	8	8	-0-	4_	A1_11/16/01	FR				X÷
Rm	R	9	7	3	8	7	2	3	10/23/97	РСТ				
1	s	9	8	3	2	8	8	0	07/30/98	PCT				
	Т.	9	8	3	2	8	9	0	07/30/98	PCT				

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

De .	<u>ٿ</u>	Astwood et al., "Stability of food allergens to digestion in vitro", Nature Biotechnology, 14:1269-1273 (1996)
	V	Bellido et al., "The phospholipid and fatty acid composition of skeletal muscle cells during culture in the presence of vitamin D-3 metabolites," Biochim Biophys Acta, 922(2):162-169 (1987)
	W	Bernkop-Schnurch, A. "The use of inhibitory agents to overcome the enzymatic barrier to peroally administered therapeutic peptides and proteins", <i>Journal of Controlled Release</i> , <u>52:</u> 1-16 (1998)
	×	Biron et al., "Natural Killer Cells In Antiviral Defenses: Function and Regulation by Innate Cytokines," Annu. Rev. Immunol., 17:189-220 (1999)
	Y	Boger et al., "Surface Probability Profiles. A Heuristic Approach to the Selection of Synthetic Peptide Antigens," Reports of the Sixth International Congress in Immunology, p. 250 (1986)
	(z)	Briand et al., "Impact of the lysine-188 and aspartic acid-189 inversion on activity of trypsin," FEBS Lett., 442(1):43-47 (1999)

EXAMINER Lizale 9	DATE CONSIDERED	4/30/	06

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>\*</sup> If an asterisk is placed beside the reference number, a copy is NOT provided because the reference was previously cited by or submitted to the PTO in a prior application, that is identified in the statement and relied upon for an earlier filing date under 35 U.S.C. 120, 37 C.F.R. § 1.98(d).

<sup>\*\*</sup> If an asterisk is placed beside the reference number, a copy is NOT provided because pursuant to the USPTO's waiver from the 37 CFR 1.98(a)(2)(i) requirement for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. national patent applications filed after June 30, 2003 and for all international applications that have entered the national stage under 35 USC 371 after June 30, 2003. See 37 CFR 1.491(b).

FORM PTO-1449	ATTY. DOCKET NO. 37851-923	SERIAL NO. CONFIRM NO. 10/658,355 3519				
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE	APPLICANT GANTIER et al.	CUSTOMER NO. 24961				
STATEMENT	FILING DATE September 8, 2003	GROUP 1044 631				

<sup>\*</sup> If an asterisk is placed beside the reference number, a copy is NOT provided because the reference was previously cited by or submitted to the PTO in a prior application that is identified in the statement and relied upon for an earlier filing date under 35 U.S.C. 120. 37 C.F.R. § 1.98(d).

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	OTHE	R ART (Including Author, Title, Date, Pertinent Pages, Etc.)
Van	ÁA"	Cockburn, A. "Assuring the safety of genetically modified (GM) foods: the importance of an holistic, integrative approach", <i>Journal of Biotechnology</i> , <u>98:</u> 79-106 (2002)
Trest	АВ	Dayhoff et al., "A Model of Evolutionary Change in Proteins," Atlas of Protein Sequence and Structure, 5(3):345-352 (1978)
L	AC :	Diaz et al., "Nomenclature of the Human Interferon Genes," J. Interferon Cytokine Res., 16:179-180 (1996)
Rh	AD	Drittanti et al., "Effects of 1,25-dihydroxyvitamin D-3 on phospholipid metabolism in chick myoblasts, Biochim Biophys Acta., 962(1):1-7 (1988)
Vm	AE	Drittanti et al., "Changes in muscle lipid metabolism induced in vitro by 1,25-dihydroxy-vitamin D-3, Biochim Biophys Acta, 918(1):83-92 (1987)
The state of the s	AF	Drittanti et al., "Involvement of the 3',5'-cyclic AMP pathway in the induction of calmodulin synthesis in myoblasts by 1,25(OH)2-vitamin D3," Biochim Biophys Res Commun., 192(2):886-892 (1993)
M	AG	Drittanti et al., "Modulation of DNA synthesis in cultured muscle cells by 1,25-dihydroxyvitamin D-3," Biochim Biophys Acta., 1014(2):112-119 (1989)
Then	АН	Drittanti et al., "Stimulation of calmodulin synthesis in proliferating myoblasts by 1,25-dihydroxy-vitamin D3," Mol Cell Endocrinol., 74(2):143-153 (1990)
My	AI	Drittanti et al., "Optimised helper virus-free production of high-quality adenoassociated virus vectors," <i>J Gene Med.</i> , 3(1):59-71 (2001)
By	AJ	Drittanti et al., "Cystic fibrosis: gene therapy or preventive gene transfer?" Gene Ther., 4(10):1001-1003 (1997)
MA	AK	Drittanti et al., "High throughput production, screening and analysis of adenoassociated viral vectors," Gene Ther., 7(11):924-929 (2000)
SIR	AL	Du et al., "Efficient transduction of human neurons with an adeno-associated virus vector," Gene Ther 3:254-261 (1996)

EXAMINER	flu	Le_	3	

DATE CONSIDERED

4/28/0B

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>\*\*</sup> If an asterisk is placed beside the reference number, a copy is NOT provided because pursuant to the USPTO's waiver from the 37 CFR 1.98(a)(2)(i) requirement for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. national patent applications filed after June 30, 2003 and for all international applications that have entered the national stage under 35 USC 371 after June 30, 2003. See 37 CFR 1.491(b).

FORM PTO-1449	ATTY. DOCKET NO. 37851-923	SERIAL NO. 10/658,355 CONFIRM NO. 3519				
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE	APPLICANT GANTIER et al.	CUSTOMER NO. 24961				
STATEMENT	FILING DATE September 8, 2003	GROUP -1644 1 6 31				

<sup>\*</sup> If an asterisk is placed beside the reference number, a copy is NOT provided because the reference was previously cited by or submitted to the PTO in a prior application that is identified in the statement and relied upon for an earlier filing date under 35 U.S.C. 120. 37 C.F.R. § 1.98(d).

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

		,,,,,,,,,,,,,,,,,,,		
Zh	ÁΜ	Feng et al., "Aligning Amino Acid Sequences: Comparison of Commonly Used Methods," J. Mol. Evol., 21:112-125 (1985)		
M2	AN	Fitch, "An Improved Method of Testing for Evolutionary Homology," <i>J. Mol. Evol.</i> , 16(1):9-16 (1966)		
M	AO	Fuchs, R.L. and J.D. Astwood, "Allergenicity Assessment of Foods Derived from Genetically Modified Plants", <i>Food Technology</i> , 50:83-88 (1996)		
M	AP	Gantier et al., "The L392V mutation of presenilin 1 associated with autosomal dominant early-onset Alzheimer's disease alters the secondary structure of the hydrophilic loop," Neuroreport, 10(14):3071-3074 (1999)		
M	AQ	Gantier et al., "The pathogenic L392V mutation of presentlin 1 decreases the affinity to glycogen synthase kinase-3 beta," Neurosci Lett., 283(3):217-220 (2000)		
Alm	AR Gibrat et al., "Surprising similarities in structure comparison," Current Opinion in Structural Biology, 6:377-385 (1995)			
ph	AS Gonnet et al., "Exhaustive Matching of the Entire Protein Sequence Database," Science, 256:1433-1445 (1992)			
Mm	АТ	Grantham,"Amino Acid Difference Formula to Help Explain Protein Evolution,"  Science, 185:862-864 (1974)		
AU Guyon et al., "Regulation of acetylcholine receptor alpha subunit variants in hum myasthenia gravis. Quantification of steady-state levels of messenger RNA in mibiopsy using the polymerase chain reaction," J Clin Invest., 94(1):16-24 (1994)				
Men	AV	Guyon et al., "Regulation of acetylcholine receptor gene expression in human myasthenia gravis muscles. Evidences for a compensatory mechanism triggered by receptor loss," J Clin Invest., 102(1):249-263 (1998)		
The same	AW	Henikoff et al., "Amino acid substitution matrices from protein blocks," Proc. Natl. Acad. Sci. USA, 89:10915-10919 (1992)		

EXAMINER LINE OF DATE CONSIDERED 4/27/06

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>\*\*</sup> If an asterisk is placed beside the reference number, a copy is NOT provided because pursuant to the USPTO's waiver from the 37 CFR 1.98(a)(2)(i) requirement for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. national patent applications filed after June 30, 2003 and for all international applications that have entered the national stage under 35 USC 371 after June 30, 2003. See 37 CFR 1.491(b).

FORM PTO-1449	ATTY. DOCKET NO. 37851-923	SERIAL NO. 10/658,355	CONFIRM NO. 3519
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE	APPLICANT GANTIER et al.	CUSTOMER NO. 24961	
STATEMENT	FILING DATE September 8, 2003	GROUP 1644 163	(

<sup>\*</sup> If an asterisk is placed beside the reference number, a copy is NOT provided because the reference was previously cited by or submitted to the PTO in a prior application that is identified in the statement and relied upon for an earlier filing date under 35 U.S.C. 120. 37 C.F.R. § 1.98(d).

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	<u> </u>	ATT (molding Address, Title, Edite, Fertillette Egee, Ess.)	
Dh	AX	Hibbert <i>et al.</i> , "Human Type 1 Inderferons Differ Greatly in Their Effects on the Proliferation of Primary B Cells," <i>J. Interferon Cytokine Res.</i> , <u>19</u> :309-318 (1999)	
Hoedemaekers et al., "Differential susceptibility of young and old rat neuron junctions to antibody-mediated AChR degradation in experimental autoimmediate myasthenia gravis," Ann N Y Acad Sci., 841:550-554 (1998)			
Hoedemaekers et al., "Role of target organ in determining susceptibility to experimental autoimmune myasthenia gravis," J Neuroimmunol., 89(1-2):131 (1998)			
Pm	ВА	Holm et al., "Mapping the Protein Universe," Science, 273:595-602 (1996)	
Am	ВВ	IUPAC-IUB "Commission on Biochemical Nomenclature Abbreviated Nomenclature of Synthetic Polypeptides (Polymerized Amino Acids)," <i>Biochem.</i> , <u>11</u> :942-944 (1972)	
The	BC IUPAC-IUB "Commission on Biochemical Nomenclature A One-Letter Amino Acid Sequences Tentative Rules", J. Biol. Chem., 243(13):35		
Am	BD	Johnson et al., "A Structural Basis for Sequence Comparisons. An Evaluation of Scoring Methodologies," <i>J. Mol. Biol.</i> , <u>233</u> :716-738 (1993)	
Mu	BE	Jones et al., "The rapid generation of mutation data matrics from protein sequences," Comput. Appl. Biosci., 8:275-282 (1992)	
Men	BF	Lu, G., "TOP: a new method for protein structure comparisons and similarity searches," <i>J. Appl. Cryst.</i> , 33:176-189 (2000)	
Dm	BG	Marrack et al., "Type I Interferons Keep Activated T Cells Alive," J. Exp. Med., 189:521-530 (1999)	
My	ВН	Masciovecchio et al., "The interactivity between the CFTR gene and cystic fibrosis would be limited to the initial phase of the disease," Genet Med., 2(2):124-130 (2000)	

EXAMINER Rule 7	DATE CONSIDERED	4/	2710	b
	 	•		

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>\*\*</sup> If an asterisk is placed beside the reference number, a copy is NOT provided because pursuant to the USPTO's waiver from the 37 CFR 1.98(a)(2)(i) requirement for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. national patent applications filed after June 30, 2003 and for all international applications that have entered the national stage under 35 USC 371 after June 30, 2003. See 37 CFR 1.491(b).

FORM PTO-1449	ATTY. DOCKET NO. 37851-923	SERIAL NO. 10/658,355	CONFIRM NO. 3519
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE	APPLICANT GANTIER et al.	CUSTOMER NO. 24961	
STATEMENT	FILING DATE September 8, 2003	GROUP 1644   6	3/

<sup>\*</sup> If an asterisk is placed beside the reference number, a copy is NOT provided because the reference was previously cited by or submitted to the PTO in a prior application, that is identified in the statement and relied upon for an earlier filing date under 35 U.S.C. 120, 37 C.F.R. § 1.98(d).

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	OTTIL	th Arti (including Author, Title, Date, Fertilient Fages, Ltc.)
Rm	BI	McLachlan, "Tests for Comparing Related Amino-acid Sequences. Cytochrome $c$ and Cytochrome $c_{551}$ ," $J.$ Mol. Biol., $\underline{61}$ :409-424 (1971)
BJ Miyata, "Two Types of Amino Acid Substitutions in Protein Evolutions in Protein Evolution Evolutions in Protein Evolution		Miyata, "Two Types of Amino Acid Substitutions in Protein Evolution," <i>J. Mol. Evol.</i> , 12:219-236 (1979)
Mes	ВК	Morikawa et al., "Recombinant interferon- $\alpha$ , - $\beta$ and - $\gamma$ enhance the proliferative response of human B cells," J. Immunol., 139:761-766 (1987)
Mr.	BL	Moulian <i>et al.</i> , "Respective role of thymus and muscle in autoimmune myasthenia gravis," <i>Ann N Y Acad Sci.</i> , <u>841</u> :397-406 (1998)
M	ВМ	Murzin et al., "SCOP: A Structural Classification of Proteins Database for the Investigation of Sequences and Structures," J. Mol. Biol., 247:536-540 (1995)
In	BN NCBI Nucleotide No. J00207	
The	ВО	Orengo et al., "CATH - a hierarchic classification of protein domain structures," Structure, 5(8):1093-1108 (1997)
Ph	ВР	Pestka, et al., "Interferons and Their Actions," Annu. Rev. Biochem., 56:727-777 (1987)
		Piehler et al., "New Structural and Functional Aspects of the Type I Interferon-Receptor Interaction Revealed by Comprehensive Mutational Analysis of the Binding Interface," J. Biol. Chem., 275:40425-40433 (2000)
BR Poëa et al., "Modulation of acetylcholine receptor expression in seronegative myasthenia gravis," Ann Neurol., 48(5):696-705 (2000)		Poëa <i>et al.</i> , "Modulation of acetylcholine receptor expression in seronegative myasthenia gravis," <i>Ann Neurol.</i> , 48(5):696-705 (2000)
pm	BS	Poëa et al., "Expression of ciliary neurotrophic factor receptor in myasthenia gravis," J Neuroimmunol., 120(1-2):180-189 (2001)
Am	ВТ	Rao, "New scoring matrix for amino acid residue exchanges based on residue characteristic physical parameters," <i>J. Pept. Protein Res.</i> , <u>29</u> :276-281 (1987)

EXAMINER Lule	3	DATE CONSIDERED	4/27/06
			•

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>\*\*</sup> If an asterisk is placed beside the reference number, a copy is NOT provided because pursuant to the USPTO's waiver from the 37 CFR 1.98(a)(2)(i) requirement for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. national patent applications filed after June 30, 2003 and for all international applications that have entered the national stage under 35 USC 371 after June 30, 2003. See 37 CFR 1.491(b).

FORM PTO-1449	ATTY. DOCKET NO. 37851-923	SERIAL NO. 10/658,355	CONFIRM NO. 3519
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE	APPLICANT GANTIER et al.	CUSTOMER NO. 24961	
STATEMENT	FILING DATE September 8, 2003	GROUP 1644   63	1

<sup>\*</sup> If an asterisk is placed beside the reference number, a copy is NOT provided because the reference was previously cited by or submitted to the PTO in a prior application that is identified in the statement and relied upon for an earlier filing date under 35 U.S.C. 120. 37 C.F.R. § 1.98(d).

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

A	AAT (including Author, Title, Date, Fertilient Fages, Ltc.)
BU	Raux et al., "The -2 bp deletion in exon 6 of the 'alpha 7-like' nicotinic receptor subunit gene is a risk factor for the P50 sensory gating deficit," <i>Mol Psychiatry</i> , 7(9):1006-1011 (2002)
в∨	Raux et al., "A novel presenilin 1 missense mutation (L153V) segregating with early-onset autosomal dominant Alzheimer's disease," <i>Human Mutat.</i> , Report #134, two pages (2000)
BW	Raux et al., "Dementia with prominent frontotemporal features associated with L113P presenilin 1 mutation," Neurol., 55(10):1577-1578 (2000)
вх	Risler <i>et al.</i> , "Amino Acid Substitutions in Structurally Related Proteins A Pattern Recognition Approach," <i>J. Mol. Biol.</i> , <u>204</u> :1019-1029 (1988)
ВҮ	Robert <i>et al.</i> , "Interferon Induces Proliferation In Leukemic And Normal B-Cell Subsets," <i>Hematol. Oncol.</i> , <u>4</u> :113-120 (1986)
BZ	Roisman <i>et al.</i> , "Structure of the interferon-receptor complex determined by distance constraints from double-mutant cycles and flexible docking," <i>Proc. Natl. Acad. Sci. USA</i> , <u>98</u> :13231-13236 (2001)
CA	Sali et al., "Definition of General Topological Equivalence in Protein Structures," J. Mol. Biol., 212:403-428 (1990)
СВ	Sanchez et al., "Spastic paraplegia and primary adrenal insufficiency: a case of adrenomyeloneuropathy," <i>Medicina (B Aires)</i> , 48(3):290-296 (1988) (Summary in English)
CC	Scheel-Toeller <i>et al.</i> , "Inhibition of T cell apoptosis by IFN-β rapidly reverses nuclear translocation of protein kinase C-δ," <i>Eur. J. Immunol.</i> , <u>29</u> :2603-2612 (1999)
CD	Shindyalov et al., "Protein structure alignment by incremental combinatorial extension (CE) of the optimal path," <i>Protein Engineering</i> , 11(9):739-747 (1998)
CE	Smith et al., "Single-step purification of polypeptides expressed in Escherichia coli as fusions with glutathione S-transferase," Gene, 67:31-40 (1988)
	BV BW BX BY CA CB CC

EXAMINER	Lusele C	7	DATE CONSIDERED	4/	26/	<u>30</u>	"
	<del></del>		<u></u>				•

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>\*\*</sup> If an asterisk is placed beside the reference number, a copy is NOT provided because pursuant to the USPTO's waiver from the 37 CFR 1.98(a)(2)(i) requirement for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. national patent applications filed after June 30, 2003 and for all international applications that have entered the national stage under 35 USC 371 after June 30, 2003. See 37 CFR 1.491(b).

FORM PTO-1449	ATTY. DOCKET NO. 37851-923	SERIAL NO. 10/658,355	CONFIRM NO. 3519
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE	APPLICANT GANTIER et al.	CUSTOMER NO. 24961	
STATEMENT	FILING DATE September 8, 2003	GROUP 4644 (63	/

<sup>\*</sup> If an asterisk is placed beside the reference number, a copy is NOT provided because the reference was previously cited by or submitted to the PTO in a prior application that is identified in the statement and relied upon for an earlier filling date under 35 U.S.C. 120. 37 C.F.R. § 1.98(d).

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

M	C	Stark et al., "How cells Respond to Interferons," Annu. Rev. Biochem., 67:227-264 (1998)
Kn	ပြ	Wakkach <i>et al.</i> , "Expression of acetylocholine receptor genes in human thymic epithelial cells: implications for myasthenia gravis", <i>J Immunol.</i> , 157(8):3752-3760 (1996)
m	GH,	Woodley, J.F. "Enzymatic Barriers for GI Peptide and Protein Delivery", <i>Critical Reviews in Therapeutic Drug Carrier Systems</i> , 11(2&3):61-95 (1994)

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: RATIONAL DIRECTED PROTEIN EVOLUTION USING TWO-DIMENSIONAL RATIONAL MUTAGENESIS

**SCANNING** 

<sup>\*\*</sup> If an asterisk is placed beside the reference number, a copy is NOT provided because pursuant to the USPTO's waiver from the 37 CFR 1.98(a)(2)(i) requirement for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. national patent applications filed after June 30, 2003 and for all international applications that have entered the national stage under 35 USC 371 after June 30, 2003. See 37 CFR 1.491(b).